文献速递胸部肿瘤

患者特征、既往治疗和样本类型对接受ATLANTIC研究筛选的晚期非小细胞肺癌患者肿瘤细胞程序性死亡配体1表达的影响

Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.
PubMed 文献 · J Thorac Oncol · 2019-05-04

该研究基于ATLANTIC研究筛选的1590例晚期非小细胞肺癌患者,评估患者特征、样本类型及既往非免疫治疗对肿瘤细胞PD-L1表达(≥25%为阳性)的影响。结果显示吸烟者、EGFR阴性者、近期转移灶样本及采样前接受化疗或放疗者PD-L1≥25%的患病率更高;近期与存档样本PD-L1状态一致率为74.0%。作者认为新鲜活检可能更准确反映当前PD-L1表达。

要点

  • 吸烟者较不吸烟者、EGFR阴性较EGFR阳性者肿瘤细胞PD-L1≥25%患病率更高,且两效应独立。
  • 近期转移灶样本较原发灶、近期样本较存档样本PD-L1≥25%患病率增加。
  • 采样前化疗或放疗与PD-L1患病率显著增加相关,酪氨酸激酶抑制无此关联。

核心结论

  • 多种因素可能影响晚期非小细胞肺癌肿瘤细胞PD-L1≥25%的患病率,但没有任何特征可作为PD-L1表达的替代指标。
  • 当存档样本显示低/阴性结果时,新鲜活检可能更准确评估当前肿瘤PD-L1表达,尤其患者接受过 intervening 治疗时。

研究设计与样本

  • 研究纳入接受ATLANTIC研究筛选的晚期非小细胞肺癌患者1590例,提交近期获取(≤3个月)或存档(>3个月至>3年)肿瘤样本,采用VENTANA PD-L1(SP263)检测,以肿瘤细胞PD-L1表达≥25%为 cutoff。
  • 样本获取于研究入组所需的两种或以上治疗方案之前或之后,样本年龄因患者而异;其中123例患者同时提供近期和存档样本。

主要发现

  • 1590例患者中517例(32.5%)肿瘤细胞PD-L1≥25%;吸烟者较不吸烟者患病率更高(p=0.0005),EGFR阴性较EGFR阳性者更高(p=0.0002),两效应独立。
  • 近期转移灶样本较原发灶样本(p=0.005)、近期样本较存档样本(p=0.039)PD-L1≥25%患病率增加。
  • 采样前接受化疗或放疗与PD-L1患病率显著增加相关,酪氨酸激酶抑制无此关联。
  • 同时提供近期和存档样本的患者中,74.0%的患者PD-L1状态(肿瘤细胞≥25% cutoff)保持不变;状态改变时,随时间或干预治疗更倾向于升高而非降低。

关键数值与推荐

  • PD-L1阳性定义为肿瘤细胞表达≥25%,采用VENTANA PD-L1(SP263)检测。
  • 吸烟者较不吸烟者PD-L1≥25%患病率更高(p=0.0005);EGFR阴性较EGFR阳性者更高(p=0.0002)。
  • 近期转移灶样本较原发灶样本PD-L1≥25%患病率更高(p=0.005);近期样本较存档样本更高(p=0.039)。
  • 近期与存档样本PD-L1状态一致率为74.0%。

临床怎么用

  • 作者认为,当存档样本显示低/阴性结果时,新鲜活检可能更准确评估当前肿瘤PD-L1表达,尤其患者接受过干预治疗时。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We evaluated the impact of patient characteristics, sample types, and prior non-immunotherapy treatment on tumor cell (TC) programmed cell death ligand 1 (PD-L1) expression using samples from patients with advanced NSCLC. METHODS: Patients (N = 1590) screened for the ATLANTIC study submitted a recently acquired (≤3 months) or archival (>3 months to >3 years old) tumor sample for PD-L1 assessment using the VENTANA PD-L1 (SP263) Assay with a cutoff of ≥25% of TCs expressing PD-L1 (TC ≥25%). Samples were acquired either before or after the two or more treatment regimens required for study entry and sample age varied among patients. A subset of patients (n = 123) provided both recent and archival samples. RESULTS: A total of 517 of 1590 (32.5%) patients had TC greater than or equal to 25%: prevalence was greater in smokers versus nonsmokers (p = 0.0005) and those with EGFR- versus EGFR+ tumors (p = 0.0002); these effects were independent. Prevalence of TC greater than or equal to 25% was increased in recent metastatic versus primary (p = 0.005) and recent versus archival (p = 0.039) samples. Chemotherapy or radiotherapy, but not tyrosine kinase inhibition, before sampling was associated with significantly increased PD-L1 prevalence. PD-L1 status (TC ≥25% cutoff) remained unchanged in 74.0% of patients with recent and archival samples; where PD-L1 status changed, it was more likely to increase than decrease over time or with intervening treatment. CONCLUSIONS: Several factors potentially impact PD-L1 TC greater than or equal to 25% prevalence in advanced NSCLC; however, no characteristic can be considered a surrogate for PD-L1 expression. Fresh biopsy may provide more accurate assessment of current tumoral PD-L1 expression where a low/negative result is seen in an archival sample, especially if the patient has received intervening therapy.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Boothman AM, Scott M, Ratcliffe M, et al. Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. J Thorac Oncol. 2019. PMID: 31063864. doi:10.1016/j.jtho.2019.04.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。